Multibagger Specialty Chemical Company Approves Rs 200 Crore Greenfield Expansion Plan; Check the Details
Join Us
Follow Us
Tatva Chintan Pharma Chem approved a Rs 200 crore capacity expansion at its Dahej-III greenfield facility, along with higher borrowing limits and the re-appointment of key directors.
✨ Key Takeaways
On Friday, Indian equity benchmarks ended higher, with the benchmark Nifty 50 index gaining 261.55 points, or 1.09 per cent, to close at 24,334.30. Amid the broader market rally, Tatva Chintan Pharma Chem share price gained 0.70 per cent to close at Rs 1,428.10 after the company's board approved a Rs 200 crore greenfield capacity expansion plan and several strategic proposals.
Tatva Chintan Board Approves Rs 200 Crore Capacity Expansion
Tatva Chintan Pharma Chem informed the exchanges that its board has approved the proposed capacity expansion at its Dahej-III greenfield manufacturing facility in Bharuch, Gujarat. The project involves the installation of an aggregate reactor capacity of 344 kilolitres (KL) with an estimated investment of Rs 200 crore. The expansion is expected to be completed over approximately 21 months and will be funded through a combination of internal accruals and debt.
The company stated that the proposed investment is aimed at meeting the anticipated increase in demand for specialty chemicals and strengthening its manufacturing infrastructure to support future growth.
Tatva Chintan Borrowing Limit Increased
To support its expansion plans, the board also approved increasing the company's borrowing limit from Rs 300 crore to Rs 1,000 crore, subject to shareholders' approval at the upcoming Annual General Meeting.
Also Read - Rs 195 Crore Order --Book: This Small-Cap Industrial Packaging Company Secures Rs 38.14 Crore HPCL Order for Composite LPG Cylinders
Management Reappointments
The board approved the re-appointment of Chintan Nitinkumar Shah as Managing Director and Ajaykumar Mansukhlal Patel and Shekhar Rasiklal Somani as Whole-time Directors for a further period of three years, effective from February 1, 2027, subject to shareholders' approval.
Tatva Chintan Q1 FY27 Financial Highlights
For the quarter ended June 2026, the company reported revenue from operations of Rs 167.1 crore, up 43 per cent YoY from Rs 116.9 crore. EBITDA increased 86 per cent YoY to Rs 32.3 crore, while profit after Tax (PAT) surged 140 per cent YoY to Rs 16 crore from Rs 6.7 crore in the corresponding quarter last year.
About Tatva Chintan
Tatva Chintan Pharma Chem Limited is a specialty chemical manufacturer engaged in the production of phase transfer catalysts, structure directing agents, electrolyte salts, pharmaceutical and agrochemical intermediates, and other specialty chemicals. The company serves customers across more than 25 countries, with exports contributing a significant share of its revenue.
The company operates manufacturing facilities in Ankleshwar, Dahej SEZ and Gujarat, supported by an in-house research and development centre. It focuses on developing sustainable specialty chemical solutions for industries including pharmaceuticals, agrochemicals, energy storage and industrial applications.
Add DSIJ as your preferred news source on G o o g l e
Add NowWhat are your views on Tatva Chintan Pharma Chem's Rs 200 crore expansion plan? Share your thoughts in the comments below.
Disclaimer: The article is for informational purposes only and not investment advice.